Upadacitinib meets all endpoints in Phase III ulcerative colitis trial
3
In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.
According to AbbVie, upadacitinib (RINVOQ™) met all its primary endpoint of clinical remission and all ranked secondary endpoints in the Phase III induction study, U-ACCOMPLISH. In the trial, a third of ulcerative colitis patients receiving upadacitinib achieved clinical remission (per Adapted Mayo Score) at week eight, compared to four percent of patients receiving placebo.
U-ACCOMPLISH (NCT03653026) is a Phase III multi-centre, randomised, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of upadacitinib 45mg taken once daily compared to placebo in adult subjects with moderate to severe ulcerative colitis. U-ACCOMPLISH is the second Phase III induction study to evaluate the safety and efficacy of upadacitinib in this indication.
Second Phase 3 Induction Study Confirms Upadacitinib ) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.